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p25α/tubulin polymerization promoting protein (TPPP) is an oligodendroglial protein that plays crucial roles including
myelination, and the stabilization of microtubules. In multiple system atrophy (MSA), TPPP is suggested to relocate from
the myelin sheath to the oligodendroglial cell body, before the formation of glial cytoplasmic inclusions (GCIs), the
pathologic hallmark of MSA. However, much is left unknown about the re-distribution of TPPP in MSA. We generated
new antibodies against the N- and C-terminus of TPPP, and analyzed control and MSA brains, including the brain of a
familial MSA patient carrying homozygous mutations in the coenzyme Q2 gene (COQ2). In control brain tissues, TPPP
was localized not only in the cytoplasmic component of the oligodendroglia including perinuclear cytoplasm and
peripheral processes in the white matter, but also in the nucleus of a fraction (62.4%) of oligodendroglial cells.
Immunoelectron microscopic analysis showed TPPP in the nucleus and mitochondrial membrane of normal
oligodendroglia, while western blot also supported its nuclear and mitochondrial existence. In MSA, the
prevalence of nuclear TPPP was 48.6% in the oligodendroglia lacking GCIs, whereas it was further decreased
to 19.6% in the oligodendroglia with phosphorylated α-synuclein (pα-syn)-positive GCIs, both showing a significant decrease
compared to controls (62.4%). In contrast, TPPP accumulated in the perinuclear cytoplasm where mitochondrial
membrane (TOM20 and cytochrome C) and fission (DRP1) proteins were often immunoreactive. We conclude that
in MSA-oligodendroglia, TPPP is reduced, not only in the peripheral cytoplasm, but also in the nucleus and relo-
cated to the perinuclear cytoplasm.
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p25α is a 25 kilodalton (kDa) phosphorylated protein,
first identified from a tau protein kinase fraction [1]. The
protein was later discovered to possess tubulin binding
ability, and was renamed as tubulin polymerization pro-
moting protein (TPPP) [2]. TPPP is expressed exclusively* Correspondence: pico.nuro@tmd.ac.jp
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unless otherwise stated.in the oligodendroglia in the central nervous system [1,3],
and plays a critical role in myelin maturation [4]. TPPP is
also essential for the reorganization and stabilization of
microtubules [2,5]. Another characteristic biochemical
feature of TPPP is that it normally remains as an unfolded
and unstructured protein without binding partners [6],
whereas in the presence of proteins such as myelin basic
protein (MBP) or tubulin [2,7-9], it changes its secondary
structure and exerts physiological roles such as binding
with tubulin to stabilize microtubules [2,5]. TPPP is
also a guanosine triphosphate (GTP)-binding protein,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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phosphate (GDP), and participates in multiple physio-
logical functions [9].
In adult human brains, TPPP is considered to be expressed
in the oligodendroglial cytoplasm including their terminal
processes, where it plays a role in forming mature myelin by
binding with MBP [8]. TPPP has also been studied in a
number of human diseases. In multiple sclerosis (MS),
demyelinated lesions show loss of TPPP-positive oligo-
dendroglial cells, whereas re-myelinating areas show
TPPP-upregulation in the oligodendroglial cytoplasm,
subsequently followed by TPPP expression in the myelin
sheath [10]. TPPP is known to accumulate in the oligogo-
dendroglia of patients with various neurodegenerative dis-
orders including Parkinson’s disease [11]. Multiple system
atrophy (MSA) is a common neurodegenerative disorder
showing parkinsonian features, cerebellar ataxia, and auto-
nomic failure, and has been suggested to be a primary
oligodendrogliopathy [12]. The neuropathologic hallmark
of MSA is the formation of argyrophilic glial cytoplasmic
inclusions (GCIs) in oligodendroglia [13,14], consisting of
α-synuclein (α-syn) [15-19]. Previous pathological studies
on human MSA brains showed that TPPP alters its distri-
bution from the myelin sheath to the cell soma where it
colocalizes with α-syn-containing GCIs [8,12].
However, much remains unknown regarding the expres-
sion of TPPP in human brains. The normal distribution
of TPPP varies among previous reports: the majority of
reports have emphasized that TPPP is expressed in the
oligodendroglial cytoplasm and all of the processes [7,8],
whereas two studies reported that TPPP is localized in the
cytoplasm and nucleus [10,20]. It is not certain if this in-
consistency is due to differences in the epitope locations
within TPPP of the antibodies utilized. Considering that
TPPP may exert various physiological functions through
its GTPase activity [9,21], it is particularly important to
confirm the location where TPPP is normally expressed,
and how it is altered in each disease.
We therefore aimed to clarify the distribution of TPPP
in normal and MSA brains. For this purpose, we gener-
ated new antibodies against the amino (N)- and carboxyl
(C)-termini of TPPP, and examined human brain tissues
including 11 MSA individuals. We not only confirmed
that TPPP colocalizes with the myelin marker MBP, but
we also found that TPPP is expressed in more than 60%
of normal, mature oligodendroglial nuclei. Immunoelctron
microscopy as well as western blotting also showed that
TPPP is located in normal oligodendroglial mitochondria.
In MSA, TPPP was lost not only from the oligodendroglial
peripheral processes including myelin sheaths, but also
from the oligodendroglial nuclei, and accumulated in its
cell body where increased immunoreactivity was also seen
for two mitochondrial membrane proteins (translocase
of the mitochondrial outer membrane 20 [TOM20] andcytochrome C), and dynamin-related protein 1 (DRP1) that
mediates mitochondrial fission. We investigated the redis-
tribution of TPPP in amyotrophic lateral sclerosis (ALS),
MS, and oligodendroglioma, and found that it was specific
to MSA. We propose the amount of nuclear TPPP is re-




Autopsies were performed with written consent from the
families, and the brain and spinal cord of the patients were
removed and immediately frozen at −80°C.
The study was approved by the Institutional Review
Boards of Ethics of Tokyo Medical and Dental University
and University of Niigata, and also conformed to the
tenets of the Declaration of Helsinki. All samples were ob-
tained either from the Department of Human Pathology,
Tokyo Medical and Dental University, Tokyo, Japan, or
from the Brain Research Institute, University of Niigata,
Niigata, Japan.
We studied patients with sporadic MSA (Cases 1–10,
12–14), familial MSA (Case 11), who was already reported
as homozygously carrying the M128V-V393A COQ2
mutation [22,23], normal controls who died from non-
neurological conditions (Cases 15–26), and disease con-
trols including ALS (Cases 27 and 28), oligodendroglioma
(Cases 29 and 30), MS (Cases 31–34) and others (Cases
35–37) (Table 1). The Case 11 as well as her/his sibling
were both clinically diagnosed as MSA-P, pathologically
confirmed as MSA (22), and whole genome sequence ana-
lysis on them lead to an identification of COQ2 mutations
in MSA (23).One of these two sibs, the only available sam-
ple upon investigation, were confirmed to show a signifi-
cantly reduced intracellular coenzyme Q10 level in her/his
brain tissue, suggesting a functional consequence of this
mutation (23).
Antibodies
The anti-TPPP rabbit polyclonal antibody named TPPP-
C-psB was raised by immunizing a rabbit with a syn-
thetic peptide corresponding to the human C-terminal
amino acid residues 204–219 (amino acid sequence:
GYKHAGTYDQKVQGGK). The peptide was coupled to
keyhole limpet haemocyanin before immunization. The
anti-serum was purified on columns containing the
synthetic peptide.
To generate the anti-TPPP rat monoclonal antibody
(TPPP-N-mab#2A8G3), rats were immunized by sub-
cutaneously injecting synthetic peptides corresponding
to the N-terminal amino acid residues 1–39 of human
TPPP (amino acid sequence: MADKAKPAKAANRTP
PKSPGDPSKDRAAKRLSLESEGAG). The spleen cells of
immunized rats were fused with myeloma cells, creating
Table 1 The individuals investigated in the present study
Case Number Diagnosis Age at death (years) Gender Disease duration
1 MSA-C 64 M 7 y
2 MSA-C 65 F 5 y
3 MSA-C 69 M 2 y
4 MSA-C 70 M 11 y
5 MSA-C 65 M 4 y
6 MSA-C 70 F 2 y
7 MSA-C 82 M 6 y
8 MSA-C 71 M 8 y
9 MSA-C 60 M 9.5 y
10 MSA-C 71 M 11y
11 MSA-P (Familial MSA) 73 F 5 y
12 MSA-C 62 F 8 y
13 MSA-P 66 M 4 y
14 MSA-C 80 F 3 y
15 lung cancer 68 M -
16 hemophagocytosis 67 M -
17 polyneuropathy 64 F -
18 gastrointestinal bleeding 75 M -
19 abdominal hemorrhage 80 M -
20 adult T-cell leukemia 55 F -
21 pneumonia 61 F -
22 acute abdomen 51 M -
23 myasthenia gravis 82 F -
24 Foix-Alajouanine syndrome 79 F -
25 pneumonia 88 M -
26 polyneuropathy 87 F -
27 ALS 61 M 1 y
28 ALS 59 M 3 y
29 oligodendroglioma 28 F 1 m
30 oligodendroglioma 62 F 16 y
31 MS 61 F 12 y
32 MS 54 M 10 y
33 MS 31 M 7 y
34 MS 80 M 13 y
35 myotonic dystrophy 78 F 23 y
36 stroke 70 M -
37 vitamin deficiency 31 M 7 y
M: male; F female; y: years; m: month.
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TPPP monoclonal antibody were identified by the en-
zyme linked immunosorbent assay and western blotting,
and were further screened by immunohistochemistry with
human brain sections, to confirm that the antibodies
recognize TPPP. Other antibodies used in this study are
summarized in Table 2.Preparation of mouse tissue samples
All animal procedures were performed according to the
protocol approved by the Animal Experiment Committee
of Tokyo Medical and Dental University. The endogenous
TPPP protein level in various mouse tissues was analyzed
by immunoblotting. Twelve-month-old C57BL/6J male
mice were sacrificed under deep pentobarbitone anesthesia,
Table 2 Primary antibodies used in the present study
Antibody Host Dilution Source
TPPP (C-ps B) rabbit 1:500 (IHC, IF) our laboratory
1:20,000 (WB)
1:20 (IEM)
TPPP (N-mab#2A8G3) rat 1:50 (IHC, IF) our laboratory
1:2000 (WB)
1:20 (IEM)
GFAP mouse 1:500 (IF) Sigma
IBA1 rabbit 1:500 (IF) Proteintech
MBP rabbit 1:500 (IF) DAKO
OLIG2 rabbit 1μg/ml (IF) IBL
actin rabbit 1:20,000 (WB) Sigma
lamin B1 rabbit 1:500 (IF) Santa Cruz
β-tubulin mouse 1:5000 (WB) BD Pharmingen
TOM20 rabbit 1:100 (IF) Santa Cruz
1:3000 (WB)
calnexin rabbit 1:20,000 Proteintech
histone H3 rabbit 1:2000 (WB) Cell Signaling
cytochrome C mouse 1:200 (IF) BD Pharmingen
DRP1 rabbit 1:200 (IHC, IF) Abcam
MFN2 rabbit 1:100 (IHC) Proteintech
pα-syn mouse 1:4000 (IHC,IF) WAKO
IHC: immnohistochemistry; IF: immunofluorescence.WB: western blotting;
IEM: immunoelectron microscopy.
Ota et al. Acta Neuropathologica Communications 2014, 2:136 Page 4 of 19
http://www.actaneurocomms.org/content/2/1/136and transcardially perfused with phosphate buffered saline
(PBS). Each organ was removed and frozen immediately
at −80°C. Each tissue was homogenized with 10 volumes
of Tissue Protein Extraction Reagent (Thermo Scientific,
Waltham, MA, USA) with protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN, USA). After
centrifuging at 20,000 g for 10 minutes, supernatants were
stored at −80°C until immunoblotting.
Fractionation of human brain
To clarify the expression pattern of TPPP, subcellular
fractionations were performed as previously described
[24,25]. All procedures were carried out in a cold room
maintained at 4°C, unless specifically described. Cerebral
white matter from the frontal cortex (0.1 g) of a normal
control (Case 26) was homogenized with six strokes of a
Potter-Elvehjem glass/Teflon homogenizer attached to a
Eurostar power-control visc (IKA, Staufen, Germany)
motorized stirrer set at 900 rpm with 10 volumes of buffer
A (0.32 M sucrose, 1 mM EDTA, 10 mM Tris–HCl, pH
7.4) containing protease inhibitor cocktail (Roche Applied
Science). The homogenate was then centrifuged at 600 × g
for 10 minutes (step 1). The pellet of step 1 should contain
the crude nuclear fraction, whereas the supernatant of step
1 should contain crude mitochondrial and cytoplasmicfractions including microsomal proteins. The crude nu-
clear fraction was diluted with 1.5 ml of 0.25 M sucrose/
TKM buffer (50 mM Tris–HCl [pH 7.5], 25 mM KCl, and
5 mM MgCl2), and then further diluted with 3.0 ml of 2.3
M sucrose/TKM buffer, yielding approximately 4.5 ml of a
1.6 M sucrose extract. This extract was then layered onto
the 2 ml of 2.3 M sucrose/buffer TKM in an SW41 centri-
fuge tube (Beckman, San Diego, CA, USA). Next, 1 ml of
0.25 M sucrose/TKM buffer was added on top, and centri-
fuged at 12,000 g for 60 minutes. The resultant second
pellet was re-suspended in 1 ml of buffer A and re-
centrifuged at 12,000 g for 10 minutes. The resultant third
pellet was re-suspended in buffer A and re-centrifuged at
3,000 g for 10 minutes. The resultant fourth pellet was
analyzed as the nuclear fraction.
The supernatant of step 1 was centrifuged at 3,000 g for
5 minutes, and the pellet was discarded. The second
supernatant was collected and centrifuged at 12,000 g for
10 minutes (step 2). The third supernatant was centrifuged
at 70,000 g for 60 minutes. The fourth supernatant was
taken as the cytosolic fraction and the fourth pellet was
microsome fraction. The resulting pellet of step 2 was sus-
pended in 1 ml of buffer A, and centrifuged at 3,000 g.
The pellet was discarded to remove contamination of nu-
clei. The supernatant was centrifuged at 12,000 g for 10
minutes. The second pellet was re-suspended in 1 ml of
buffer A and re-centrifuged at 12,000 g for 10 minutes.
The resulting pellet was considered as the mitochondrial
fraction. All fractions were stored at −80°C until analysis.
When analyzing with immunoblotting to provide the evi-
dence that nuclear fraction contains TPPP, 180 ng of cyto-
solic, mitochondrial and nuclear proteins are loaded into
each lane. To examine if microsomal fraction contains
TPPP, 1.0 μg protein obtained from the second super-
natant which should contain cytosolic, mitochondrial
and microsomal fractions, 500 ng protein obtained from
the third supernatant which should contain cytosolic and
microsomal fractions, and another 500 ng protein ob-
tained from the fourth pellet which should be the micro-
somal fraction, were prepared and loaded.
Immunoblotting
Western blotting analysis was performed as described
previously [25]. Transfer and detection were carried out
according to the protocol provided with the ECL Detec-
tion System (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). Horseradish peroxidase-conjugated anti-mouse
immunoglobulin G (IgG), anti-rabbit IgG, or anti-rat IgG
(diluted 1:20,000, Jackson ImmunoResearch, Baltimore,
PA, USA) was used as a secondary antibody.
Immunohistochemistry
Human brains fixed in formalin and embedded in par-
affin were used. Four-micrometer-thick sections were
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and boiled for 5 minutes twice in 10 mM citrate buffer
(pH 6.5). For TPPP immunohistochemistry, sections were
subsequently immersed in formic acid for 5 minutes. All
sections were treated with 0.3% (v/v) hydrogen peroxide
in distilled water to quench the endogenous peroxide, and
then incubated with normal goat, horse or rabbit sera as
appropriate, for 30 minutes. Finally, sections were incu-
bated with primary antibodies overnight at 4°C. The
primary antibodies were detected with the Vectastain
ABC rabbit, mouse or rat IgG kits (Vector Laboratories,
Burlingame, CA, USA), and visualized using Histofine
Simple Stain DAB (Nichirei Bioscience, Tokyo, Japan) ac-
cording to the manufacturer’s protocol. Between each step,
sections were washed three times with PBS containing
0.1% Triton-X.Immunofluorescence
For immunofluorescent labeling, sections were treated
similarly to the immunohistochemistry procedure. The
primary antibodies were detected by a one hour incuba-
tion at room temperature using either one of the following
five secondary antibodies: FITC-conjugated horse anti-
mouse IgG (Vector Laboratories), Alexa 555-conjugated
goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA),
Alexa 488-conjugated goat anti-rat IgG(Cell Signaling
Technology, Danvers, MA, USA), Alexa 555-conjugated
goat anti-rabbit IgG (Invitrogen), Alexa 647-conjugated
goat anti-rabbit IgG (Invitrogen) (all at 1:250 dilution).
Sections were examined under a confocal laser scanning
microscope (LSM 510META, Carl Zeiss, Jena, Germany).Immunoelectron microscopy
Four-week-old C57BL6/J male mice were deeply anes-
thetized, perfused with 4% paraformaldehyde, and
their white matter was removed. For the immunocryo-
ultramicrotomy, samples were fixed in 4% paraformal-
dehyde in 0.1 M PBS for 30 minutes, and then
immersed in 2.3 M sucrose in 0.1 M PBS for 24 hours
at 4°C. The samples were mounted on a holder, frozen
quickly with liquid nitrogen, and then cut using an
ultracut S microtome (Reichert, Vienna, Austria) equipped
with a Freezing Cryo Sectioning (FCS) system (Reichert).
Frozen ultrathin (90 nm) sections were collected on
formvar-coated nickel grids and then placed on droplets
of 1% BSA in 0.1 M PBS. The sections were subsequently
transferred to droplets of TPPP-C-psB (diluted in 1:20
with 1% BSA in 0.1 M PBS) for 12 hours at 4°C, washed
with 0.1 M PBS, and incubated with goat anti-rabbit IgG
conjugated with 10-nm gold colloidal particles (diluted
1:20 with 1% BSA in 0.1 M PBS, British Bio Cell Inter-
national, Cardiff, UK) for 12 hours at 4°C. Subsequently,
sections were stained with 1% uranyl acetate, washed withdistilled water, and finally embedded with a mixture of 3%
polyvinyl-alcohol and 0.3% uranyl acetate.
For the post-embedding method, samples were fixed
in 4% paraformaldehyde in 0.1 M PBS for 30 minutes,
and dehydrated and embedded in LR White resin. Ul-
trathin sections were prepared and mounted on nickel
grids. After incubation with 10% normal goat serum for
10 minutes, sections were incubated overnight at 4°C
with TPPP-N-mab#2A8G3 (diluted 1:20 with 1% BSA
in 0.1 M PBS). We also created control samples by
omitting only the primary antibodies and treating the
rest of the procedures similarly. After washing with
PBS, the sections were incubated with a mixture of goat
anti-rat IgG conjugated to 15-nm gold particles (diluted
1:30 with 1% BSA in 0.1 M PBS, British Bio Cell Inter-
national) for 2 hours at room temperature. The sections
were then washed with water and stained with uranyl
acetate. All sections were examined by transmission
electron microscopy (H-7100; Hitachi High Technologies,
Tokyo, Japan).
We randomly collected 62 mitochondria containing
immune-gold particles, and analysed where the gold
particles were located.
Analysis of TPPP-immunoreactivity in the oligodendroglial
nucleus
Presence of TPPP-immunoreactivity in the oligodendroglial
nuclei could be assessed in single immunohistochemistry
for TPPP. To confirm its nuclear existence, we also per-
formed a double immunofluorescence study for TPPP
using TPPP-N-mab#2A8G3 and an inner nuclear mem-
brane marker lamin B1 (Table 2) and analyzed in three
dimension.
Analysis of the relationship between TPPP and GCI in
MSA-oligodendroglia
The cerebral cortex and nearby white matter of the
precentral gyrus, temporal and occipital lobes, putamen,
cerebellum and pons were studied in selected cases.
Next, the precise sequential relationship between TPPP
re-localization and the emergence of α-syn-positive
structures in MSA-oligodendroglia were studied in 20
individuals consisting of 10 patients with MSA (Cases
1–10) and 10 normal controls (Cases 15–24) (Table 2).
Sections were subjected to triple-labeling immunofluor-
escence using TPPP-N-mab#2A8G3, a commonly used
mouse monoclonal anti-phosphorylated α-synuclein
(pα-syn) antibody (Wako, Tokyo, Japan, Table 2), and
Hoechst for nuclear staining. Then, the sections were
analyzed by a confocal laser scanning microscope (Carl
Zeiss) with merged digital images.
We classified the oligodendroglia into six types
based on the previous literatures (8, 27) and the com-
bination of labeling patterns of TPPP and the presence
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the MSA-oligodendroglia into two groups according to
their nuclear TPPP: those with nuclear TPPP immunore-
activity within the nucleus showing co-localization of
Hoechst and TPPP (types 1, 3 or 5) and those without
(types 2, 4 or 6). The oligodendroglia with both nuclear
and cytoplasmic TPPP-immunoreactivities were classified
as nuclear type, since the TPPP is basically a cytoplasmic
protein. The oligodendroglia with pα-syn-positive GCIs
was further classified into four types (types 3–6) according
to the location of TPPP immunoreactivity; type 3: oligo-
dendroglia with both nuclear and cytoplasmic TPPP;
type 4: oligodendroglia with exclusively cytoplasmic
TPPP; type 5: oligodendroglia with exclusively nuclear
TPPP (i.e., there is no co-localization of TPPP with
GCI); type 6: oligodendroglia without any TPPP-
immunoreactivity, but solely with pα-syn-positive GCIs.
We randomly took photographs from 20 fields, and each
oligodendroglia in these fields was classified. For type 1
and 2 oligodendrocytes, 100–150 cells were classified in
each MSA and control case. For type 3–6 cells, 100–150
GCI-positive oligodendrocytes were counted randomly in
each MSA case, and classified into types 3–6. As we fo-
cused on the prevalence of nuclear TPPP, we calculated
the frequency of oligodendroglia that have TPPP in their
nuclei in four distinct classes of oligodendroglia: 1) oligo-
dendroglia without pα-syn-immunoreactivity (i.e., type 1/
types 1 + 2); 2) all oligodendroglia with GCIs (i.e., types
3 + 5/types 3 + 4 + 5 + 6 in MSA); 3) oligodendroglia
having TPPP-positive GCIs (i.e., type 3/types 3 + 4); 4)
oligodendroglia having TPPP-negative GCIs (type 5/
types 5 + 6). Finally, the frequencies of nuclear TPPP
were compared using the Mann–Whitney test in 1)
type 1/types 1 + 2 in MSA vs normal controls, 2) type
1/types 1 + 2 vs types 3 + 5/types 3 + 4 + 5 + 6 in MSA,
and 3) type 3/types 3 + 4 vs type 5/types 5 + 6 in MSA.
P values < 0.05 were considered to indicate a statisti-
cally significant difference between groups.
Computer prediction of the classical nuclear localization
signal in human TPPP
Prediction of the classical nuclear localization signal spe-
cific to the importin α/β pathway in budding yeast was
performed by inputting the full-length TPPP amino acid
sequence into cNLS Mapper (http://nls-mapper.iab.keio.
ac.jp). With this prediction system, an NLS with a score
of 8, 9, or 10, suggests that the protein is exclusively lo-
calized to the nucleus, that with a score of 7 or 8 partially
localized to the nucleus, that with a score of 3, 4, or 5 lo-
calized to both the nucleus and the cytoplasm, and that
with a score of 1 or 2 localized to the cytoplasm. When
we tested a canonical cytoplasmic protein beta-tubulin
(GenBank: AAB59507.1), there was no score indicating no
NLS in the entire amino acid sequence of the beta-tubulin. On the other hand, when we tested TAR DNA-
binding protein 43 [Homo sapiens; the National Center
for Biotechnology Information (NCBI) Reference Sequence:
NP_031401.1], a predicted score of 5.7 was produced.
Results
Two novel antibodies recognize endogenous TPPP that is
specifically expressed in the oligodendroglia
The TPPP-C-psB and TPPP-N-mab#2A8G3 antibodies
recognized endogenous mouse TPPP, and this recognition
was blocked by the addition of immunogenic peptides
(Figure 1a). Specificities of these two antibodies were also
confirmed by testing absorptions in human frozen brain
tissues (data not shown).Western blot analyses using these
anti-TPPP antibodies on various mouse tissues consist-
ently demonstrated a clear single band at 25 kDa, exclu-
sively in the brain (Figure 1b). This brain-specific pattern
of expression is compatible with a previous study using
rats [3]. Upon immunohistochemical analysis, we found
that the TPPP antigen was better retrieved by first boiling
in citrate buffer in a microwave and then immersing it
into formic acid for five minutes (Figure 1c), than by
treating it with either one of these procedures only
(Figure 1d). With this method, TPPP was found to be
expressed most intensely in the white matter (Figure 1e
& f) in low magnification. On a higher magnification,
the TPPP immunoreactivity was seen not only in the
oligodendroglial cell soma, processes and myelin sheath,
but also in some oligodendroglial nuclei (Figure 1g & h).
Of note is that the two antibodies showed the same expres-
sion patterns in immunohistochemistry, suggesting that
the full-length TPPP protein is contained in the nucleus.
TPPP is expressed in the nucleus of oligodendroglia
Double-labeling immunofluorescence of control human
cerebellum revealed that TPPP clearly merges with MBP
expressed mainly in the white matter, indicating that TPPP
is strongly and diffusely expressed in the oligodendroglial
cell body (Figure 2a-d). OLIG2, a well-known oligo-
dendroglial nuclear marker, colocalized with TPPP,
demonstrating that some of the TPPP immunoreactivity is
in the oligodendroglial nucleus (Figure 2e-h). Notably,
TPPP immunoreactivity was also seen in the oligodendro-
glial cell soma and their processes (Figure 2f & h, arrow-
heads). In contrast to the clear merging of TPPP with
MBP or OLIG2, TPPP did not merge with GFAP or IBA1
(Figure 2i-p), demonstrating that TPPP is not present in
astroglia or microglia, respectively. We further performed
double-labeling immunofluorescence against TPPP and
lamin B1, a marker for the inner nuclear membrane, and
confirmed that TPPP clearly localizes in the nucleoplasm
using three-dimensional images (Figure 2q). These obser-
vations led us to believe that TPPP is not only present in
the cytoplasm and processes including its terminal myelin
Figure 1 Two novel antibodies, TPPP-C-psB and TPPP-N-mab#2A8G3 recognize endogenous TPPP that is specifically expressed in the
brain. a: TPPP-C-psB and TPPP-N-mab#2A8G3 both specifically recognize a 25 kDa protein in the mouse brain. These reactions are blocked by ab-
sorption tests (peptide (+)). b: Western blots of the homogenates of various organs from an adult mouse demonstrate that TPPP is a brain-
specific protein. c & d: Some glial nuclei in the cerebellar white matter as well as perinuclear cytoplasm and neuropil show TPPP-immunoreactivity
using TPPP-C-psB (c), while this was not obvious in most cells when formic acid treatment was omitted (d) (Case 25). e-h: Immunohistochemistry using
TPPP-C-psB (e & g) and TPPP-N-mab#2A8G3 (f & h) in normal control cerebellum (Case 25). The white matter (e & f) are stained intensely, whereas,
granular (* in e and f) and molecular († in e and f) layers in the cortex are not. In addition to neuropil and perinuclear structures, TPPP-immunoreactivity
is seen in some glial nuclei (g & h, peptide (−)). These reactions are also blocked by absorption tests (g & h, peptide (+)). Scale bar = 50 μm (c, d),
200 μm (e, f), 20 μm (g, h).
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glia. However, some oligodendroglia were devoid of nu-
clear immunoreactivity (Figure 2r, arrow), demonstrating
that oligodendroglia are heterogeneous with regard to the
presence of nuclear TPPP.Location of TPPP investigated by immunoelectron
microscopy and immunoblotting
To clarify the intracellular localization of TPPP in normal
oligodendroglia, we next performed immunoelectron mi-
croscopy of 4-week-old male C57BL6/J mouse brains.
Figure 2 (See legend on next page.)
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Figure 2 Double-labeling immunofluorescence studies demonstrating the localization of TPPP throughout the oligodendroglia, including
the nucleus. Staining was performed for myelin basic protein (MBP) (a, d), OLIG2 (e, h), GFAP (i, l), and IBA1 (m, p), in the cerebellum of a
control case (Case 25). a-d: Most of the MBP immunoreaction (a) appears co-localize with TPPP immunoreaction (b) in the cerebellar folial white
matter. e-h: TPPP colocalizes with OLIG2 expressed in the oligodendroglial nucleus. Note that additional TPPP staining that does not colocalize with
the OLIG2 staining (f & h, arrowheads), suggesting that TPPP is expressed also in the oligodendrolglial cytoplasm. i-l: TPPP (j) does not colocalize with
the astroglial marker GFAP (i). m-p: TPPP (n) does not colocalize with the microglial marker IBA1 (m). q: Three-dimensional images of double-labeling
immunofluorescence against TPPP and lamin B1 reveal that TPPP additionally localizes in the nucleus of oligodendroglia. r: Not every oligodendroglia
shows nuclear TPPP staining. An arrow indicates an oligodendroglia without nuclear staining, whereas an arrowhead indicates an oligodendroglia with
nuclear TPPP staining. a-q: TPPP-N-mab#2A8G3, r: TPPP-C-psB. Scale bar = 200 μm (a-d), 10 μm (e-p), 20 μm (q, r).
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(cryo-ultramicrotomy and post-embedding preparation)
both consistently demonstrated gold particle deposits in
the nucleus as well as the cytoplasm of oligodendroglia
(Figure 3a-d). There were no particles in endothelial cells
(Figure 3e & f) or in control samples that were similarly
treated with normal goat serum instead of the ant-TPPP
antibody (Figure 3g & h). We also noted that gold particles
were localized to mitochondria. When we randomly col-
lected 62 mitochondria containing immune-gold particles,
96 out of a total of 118 particles (81.4%) were located in
the outer mitochondrial membrane (Figure 3i, arrows).
This suggests that TPPP exists at least in the outer mito-
chondrial membrane.
We also separated the control brain tissue (frontal white
matter of Case 26) into nuclear, cytosolic, microsomal and
mitochondrial fractions, and analyzed them by western
blotting. TPPP was detected not only in the cytosolic frac-
tion, but also in the nuclear and mitochondrial fractions
(Figure 3j). On the other hand, TPPP was not detected in
the microsomal fraction (Figure 3k).
TPPP contains nuclear localization signals
Considering the molecular size of TPPP (25 kDa), it is
possible that TPPP passively diffuses into the nucleus in-
stead of being actively transported. To gain further infor-
mation, we analyzed the amino acid sequence of TPPP
using cNLS Mapper (http://nls-mapper.iab.keio.ac.jp).
The software predicted three potential bipartite nuclear
localization signals (NLSs) in human TPPP: 1) amino
acids 6–34: KPAKAANRTPPKSPGDPSKDRAAKRLSLE,
with a score of 4.1; 2) amino acids 52–82: EEAFRRFA
VHGDARATGREMHGKNWSKLCKD, with a score of 5.3;
3) amino acids 100–130: FSKIKGKSCRTITFEQFQEALEE
LAKKRFKD, with a score of 4.5. The scores ranging from
4.1 to 5.3 suggest that TPPP shuttles between the nucleus
and cytoplasm by the importin α/β pathway [26].
TPPP levels are reduced in the nucleus of MSA-
oligodendroglia
As we found that TPPP normally localizes to the nucleus
and mitochondria of oligodendroglia in both human and
mouse brains, we then examined if the localization of
TPPP is altered in MSA. Immunohistochemistry for TPPPin the pons of control individuals (Figure 4a-c) and MSA
patients (Figure 4d-g) showed that TPPP is diminished in
MSA in the neuropil (Figure 4f) and accumulated in the
perinuclear cytoplasm of oligodendroglia (Figure 4f and g),
corresponding to the relocalization of TPPP from the mye-
lin sheath to the cytoplasm, as previously described [8,12].
In addition, we noticed that oligodendroglia possessing a
swollen perinuclear cytoplasm with dense TPPP immuno-
reactivity frequently show loss of TPPP immunoreactivity
in their nuclei (Figure 4f and g). Consistently, double-
labeling immunofluorescence against TPPP and lamin
B1 showed that TPPP was absent in the nuclei of the
majority of MSA-oligodendroglia (Figure 4h). Importantly,
TDP43 and OLIG2, two nuclear proteins expressed in
oligodendroglia, were both retained in the nucleus
(Figure 4i), suggesting that the reduction of TPPP from
the nucleus of oligodendroglia is not a mere conse-
quence of cellular demise. These findings were consist-
ent in other brain areas showing degeneration, such as
the precentral gyrus, putamen, and cerebellum (data
not shown). In contrast, TPPP was retained in many
oligodendroglia in the occipital cortex, where no obvi-
ous pathological changes were seen. Therefore, loss of
nuclear TPPP immunoreactivity appears to correlate
with the degree of oligodendroglial pathologic changes.
We chose the pontine base from all available areas to
study if MSA-oligodendroglia lose their nuclear TPPP.
Conforming to a classification of MSA-oligodendroglia
reported by Huang and Halliday’s group [8,27] we classi-
fied MSA-oligodendroglia in the pontine base into six types
(Figure 4i, refer to the material and methods), and com-
pared them with the data of control oligodendroglia. Briefly,
type 1, 3 or 5 cells have nuclear TPPP, type 2, 4 or 6 cells
don’t have nuclear TPPP. Type 1 and 2 oligodendroglia are
pα-syn negative cells, type 3–6 oligodendroglia are pα-syn
positive cells. Type 1 and 2 MSA oligodendrocytes are those
lacking pα-syn-positive GCIs, which are equivalent to the
early pathological oligodendroglia in MSA as described previ-
ously [8,27]. The type 3 and 4 cells are middle stage, 5 and 6
cells are consistent with the late stage oligodendroglia in pre-
vious studies [8,27]. Although some reports define GCIs to
include those with TPPP-positive cytoplasmic structures, we
here defined “GCIs” as the cytoplasmic structures with pα-
syn-immunoreactivity irrespective of TPPP-immunoreactivity.
Figure 3 TPPP in the nucleus and mitochondria of oligodendroglia. a & b: Immunocryo-ultramicrotomy analysis of an adult mouse brain using
TPPP-C-psB. A high magnification view of the square in panel (a) depicts gold particles in both the perinuclear cytoplasm and nucleus (b). c, d:
Immunoelectron microscopy of a post-embedded sample using TPPP-N-mab#2A8G3. A high magnification view of a square in the panel (c)
demonstrates gold particles again in the cytoplasm and nucleus (d). e, f: Gold particles are not seen on endothelial cells. g, h: Non-specific
reactions were not seen on the samples treated with normal goat serum. i: Gold particles were also seen in mitochondria (arrows). a b & j:
TPPP-C-psB, c-f & i: TPPP-N-mab#2A8G3. Scale bar = 500 nm (a, d, f, h, i), 100 nm (b), 1 μm (c), 2μm (e, g). j: Western blotting analysis of subcellular
fractionation samples from human frontal lobe tissue (Case 26). TPPP-C-psB was used to detect TPPP. Anti-β-tubulin, anti-TOM20, anti-histone
H3 antibodies were used as a fractionation control of cytosolic, mitochondrial and nuclear proteins, respectively. The results indicate that TPPP
is present not only in the cytosolic, but also in the mitochondrial and nuclear fractions. Considering that comparable amounts of proteins are
loaded, the TPPP is contained in the mitochondrial fraction (j). k: The TPPP is not detected in the protein fraction (lane 3) which contains
calnexin-positive microsomal proteins, but devoid of mitochondrial (TOM20) and cytosolic (β-tubulin) proteins.
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in the MSA-oligodendroglia that did not possess obvious
GCIs (i.e., type 1 & 2 oligodendroglia) (type 1/types 1 +
2 in MSA = 48.63 ± 10.37% vs type 1/types 1 + 2 in con-
trols = 62.4 ± 13.5%, p = 0.0185) (Figure 4k). As type 1
and 2 oligodendroglia are considered to be in the rela-
tively early stages of the pathogenic cascade of MSA[8,27], the significant reduction of nuclear TPPP appears
to be a relatively early phenomenon that precedes GCI
formation. In addition, the MSA-oligodendroglia con-
taining a GCI (i.e., a pα-syn-positive cytoplasmic struc-
ture) had much less TPPP in the nucleus (types 3 + 5/
types 3 + 4 + 5 + 6 in MSA = 19.6 ± 10.9%) than in the
GCI-negative MSA-oligodendroglia (type 1/types 1 + 2
Figure 4 (See legend on next page.)
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Figure 4 Nuclear TPPP staining is reduced in MSA oligodendroglia. a-c: Klȕver-Barrera staining (a) and an immunohistochemistry for TPPP
(TPPP-C-psB) in normal control pons (Case 19). Note that myelin structures mostly show TPPP-immunoreaction, though this correlation is not always
true as in the medial lemniscus and superior cerebellar peduncle. A higher magnification of (b) show TPPP-immunoreactivity in neuropil and in nuclei
(c). d-g: In MSA-pons (Case 8), loss of myelin structure in Klȕver-Barrera staining (d) is also observed in an immunohistochemistry for TPPP (TPPP-C-psB)
(e). Where the TPPP immunoreactivity is very low (f), TPPP-positive cells are very few, suggesting oligodendroglial cell loss. In an area with relatively
stronger TPPP-immunoreactivity (g), TPPP-positive oligodendroglia are remaining. Note that MSA-oligodendroglia (f & g) tend to lack nuclear-TPPP
immunoreactivity compared to control (c). h: A three-dimensional image of double-labeling immunofluorescence of an MSA-cerebellum (Case 1) using
TPPP-N-mab#2A8G3 and the anti-lamin B1 antibody. Note that nuclear TPPP is absent and the TPPP-immunoreactive cytoplasm is widened in this cell.
i: Double-labeling immunofluorescence demonstrating the localization of TPPP (TPPP-N-mab#2A8G3) and TDP43, or TPPP and OLIG2 in the MSA-
cerebellum (Case 1). TDP43 and OLIG2 are retained in the nucleus, whereas TPPP is absent. j: Classification of oligodendroglia into six types based on
the localization of TPPP (TPPP-N-mab#2A8G3) and pα-syn. Hoechst staining is omitted from this figure. k: Box and whisker plot demonstrating
the frequency of oligodendroglia with TPPP immunoreactivity in the nucleus. Compared with the normal control, nuclear TPPP is significantly reduced
in pα-syn-negative MSA-oligodendroglia (type 1/types 1+2). The reduction of TPPP in the nucleus was more pronounced in MSA-oligodendroglia with
GCIs (types 3+5/types 3+4+5+6). Nuclear TPPP was also reduced in oligodendroglia containing TPPP-negative GCIs (type 5/types 5+6) than in those
containing TPPP-positive GCIs (type 3/types 3+4). *p<0.05, (k). Scale bar=5 mm (a, b, d, e), 20 μm (c, f, g), 10 μm (h, j), 5 μm (i).
Ota et al. Acta Neuropathologica Communications 2014, 2:136 Page 12 of 19
http://www.actaneurocomms.org/content/2/1/136in MSA= 48.63 ± 10.37%, p < 0.001). Among the oligo-
dendroglia with GCIs (types 3–6), the prevalence of nuclear
TPPP was almost negligible in those without cytoplasmic
TPPP (types 5 and 6; type5/types 5 + 6 in MSA= 0.69 ±
1.47%), demonstrating that type 5 (exclusively nuclear
TPPP with a GCI) oligodendroglia are very rare. Overall,
the present observations suggest that the level of TPPP in
the nuclei of oligodendroglia is reduced at an early stage,
before the obvious formation of a GCI (type 2) or swelling
of the cytoplasm (type 4), and is followed by its eventual
disappearance from oligodendroglia (type 6), at least in the
pontine base that we analyzed. The pα-syn-positive glial
nuclear inclusions (GNIs), neuronal cytoplasmic and nu-
clear inclusions (NCIs and NNIs) were so few that they
could not be statistically analyzed. The relationship between
TPPP and any of these structures will be separately investi-
gated on different samples.
Distribution of TPPP in other neurological diseases
To confirm that the relocalization of TPPP is specific to
MSA, we performed immunohistochemistry for TPPP in
the brains of patients with ALS, oligodendroglioma, and
MS. The precentral gyrus of ALS patients exhibited no
notable changes compared to normal controls (Figure 5a).
In the brain tissue affected with oligodendroglioma, there
was a lack of TPPP immunoreactivity (Figure 5b-d), con-
sistent with a previous report [28].
In MS, the demyelinating areas consistently showed
loss of TPPP immunoreactivity from the peripheral mye-
lin (Figure 5e-g). However, two distinct patterns were
additionally noted in terms of nuclear TPPP. One was a
complete disappearance of TPPP from oligodendroglial
nuclei, resulting in total loss of TPPP (Figure 5h). Such
areas showed intense demyelination (Figure 5e). The
other pattern was an increased TPPP staining in some
oligodendroglial cell body and nuclei, with loss of TPPP
from myelin (Figure 5e). Such areas showed relatively
mild demyelination (Figure 5i). Although strong TPPP
expression in the oligodendroglial nuclei has previouslybeen reported, it has not received much attention [10].
It may be possible that the increase of nuclear TPPP
reflects a certain defense mechanism in the oligo-
dendroglia against cell death, or a regeneration process
of oligodendroglia.
TPPP accumulates in cytoplasm preceding pα-syn deposition
in MSA-oligodendroglia along with mitochondrial proteins
Since the results of immunoelectron microscopy and
western blotting after cellular fractionation both revealed
that TPPP exists in mitochondria, immunofluorescence
analysis for TPPP and the four mitochondrial proteins,
TOM20 (a marker for the outer mitochondrial membrane),
cytochrome C (a marker for the inner mitochondrial mem-
brane), DRP1 and mitofusin2 (MFN2) [29] were performed
using specific antibodies (Table 2).
In normal oligodendroglia, few small TOM20-
immunoreactive granules were identified in the cyto-
plasm (Figure 6a-d). Similarly, granular cytochrome C
immunoreactivity was observed in the oligodendroglial
cell body (Figure 6e-h). In contrast, both TOM20
(Figure 6i-l) and cytochrome C (Figure 6m-p) were
intensely and diffusely stained in the swollen cell bodies of
MSA-oligodendroglia, suggesting the accumulation of
mitochondrial proteins in this pathologic condition.
To see if any disturbance in mitochondrial function
occurs in the MSA-oligodendroglia, we finally investigated
an important mitochondrial fission protein, DRP1, and a
representative mitochondrial fusion mediator, MFN2 [29].
Immunoreactivities for MFN2 and DRP1 were both rela-
tively stronger in neurons than in oligodendroglia in
control tissues (Figure 7a and b, left columns). In MSA,
MFN2 was also not immunoreactive (Figure 7a, right
columns). Compared to such weak immunoreactivity,
the DRP1-immunoreactivity was slightly increased in
MSA oligodendroglia as well as in neurons (Figure 7b,
right columns). In terms of the different stages of MSA-
oligodendroglia, we found that DRP1-immunoreactivity was
relatively stronger in GCI-containing MSA-oligodendroglia
Figure 5 TPPP relocalization is specific to MSA. a: Normal staining of TPPP (TPPP-C-psB) of the frontal lobe of a patient with ALS(Case 27).
b-d: A biopsy specimen with oligodendroglioma (Case29). Tumor mass (* in b and c) is devoid of TPPP-immunoreactivity whereas the reaction is
seen in the nearby normal region (# in b and d) (antibody: TPPP-C-psB). e-i: A parietal lobe sample from a patient with MS (Case 31). Two corresponding
panels from Klȕver-Barrera staining (e) and an immunohistochemistry for TPPP (TPPP-C-psB) (f) suggest reduced TPPP-immunoreactivity correlates with
myelin loss. Relatively less affected area (¶ in e, f and g) shows almost normal TPPP pattern (g). In an area with severe demyelination († in e, f and h), TPPP
was nearly completely lost (h). In a different area with a milder demyelination (‡ in e, f and i), some oligodendroglia showed TPPP-immunoreactivity in their
nuclei (i). a, b-d, f-i: TPPP-C-psB. Scale bar = 50 μm (a-i), 5 mm (b, e, f).
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was observed even in the type 2 TPPP-positive (but pα-
syn-negative) oligodendroglia (Figure 7c, left column,
arrow). Similarly, TOM20 was also observed in type 2
MSA-oligodendroglia (Figure 7c, right column, arrow-
head). These may indicate that some of the mitochondrial
proteins exemplified by DRP1 and TOM20 are accumu-
lated in the cell bodies of MSA-oligodendroglia, possibly
before the obvious formation of pα-syn-positive GCIs.
We tested if the mitochondrial protein TOM20 is up-
regulated in the subcortical white matter of the precentral
gyrus in MSA. However, we did not observe significant
changes in MSA samples compared to controls. We con-
sider that this western blot result does not preclude mito-
chondrial accumulation in MSA oligodendroglia observed
in immunohistochemistry, as the TOM20 protein level
can be influenced not only by oligodendroglia, but also by
many other cells including astrocytes, microglia and neur-
onal processes that express TOM20.
Pathology of familial MSA with homozygous COQ2mutations
To investigate the pathological features of MSA with
defective COQ2 variants, we studied Case 11, who hadhomozygous for the M128V-V393A COQ2 mutations.
Immunohistochemistry revealed pα-syn-positive GCIs
(Figure 8a), abnormal TPPP distribution (Figure 8b)
and DRP1-immunopositive oligodendroglia (Figure 8c).
In addition, DRP1 and TOM20 co-localized with pα-syn,
and accumulated in GCIs, similarly to the findings in
sporadic MSA (Figure 8d-k). Although only one case was
available for the present analysis, these results demon-
strate that the COQ2 mutation, leading to Coenzyme Q10
deficiency, causes TPPP relocation. Furthermore, identical
TPPP redistribution in our sporadic and familial MSA
samples suggests that the redistribution of TPPP and the
abnormal accumulation of mitochondrial proteins are a
common pathway in the MSA pathophysiology of both
sporadic and familial cases.
Discussion
By generating two antibodies against TPPP, we here con-
firmed that TPPP is expressed exclusively in the brain,
and further that the expression is restricted to oligo-
dendroglia, as previously reported [3]. We also found
that TPPP is expressed abundantly in the cytoplasm
and processes including the myelin sheath as previously
Figure 6 TPPP relocates to the cytoplasm with the mitochondrial membrane markers TOM20 and cytochrome C in MSA-oligodendroglia.
Double-labeling immunofluorescence of TPPP (TPPP-N-mab#2A8G3), TOM20, and cytochrome C in a control (a-h) (Case 16) and an MSA patient
(i-p, Case 1). a-d: In normal oligodendroglia, TOM20 (a), a marker of the outer mitochondrial membrane, is detected as few small granules in the
cytoplasm, whereas TPPP immunoreactivity is seen diffusely in the cytoplasm (b). e-h: Similarly, cytochrome C (e), an inner mitochondrial
membrane marker, is observed as granules in normal oligodendroglia. i-l: In an MSA-oligodendroglia, TOM20 is accumulated in the swollen
perinuclear cytoplasm (i), with a similar pattern with TPPP (l). m-p: In another MSA-oligodendroglia, cytochrome C is accumulated in the large
perinuclear cytoplasm (m), again in a similar pattern with TPPP (n). All scale bars = 10 μm.
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of about 62% of normal oligodendroglia, when analyzed in
the pontine base. Considering that oligodendoglia are a
group of cells with different biochemical and metabolic
properties [30], it is not surprising that TPPP is not
observed in all oligodendroglial nuclei. The presence of
TPPP in the nucleus was consistent: it was demonstratedby (1) immunohistochemical and immunoelectron micro-
scopic analyses of human and mouse brain tissues, (2)
double-labeling immunofluorescence analysis for TPPP
and lamin B1 with three-dimensional visualization and (3)
western blotting of nuclear, cytosolic and mitochondrial
fractions of human brain homogenates. Whereas most
previous reports emphasized that TPPP was expressed in
Figure 7 The immunoreactivities for the mitochondrial fission marker DRP1 and the outer membrane marker TOM20 are both increased in
the MSA-oligodendroglial cytoplasm before the obvious formation of GCIs. a: MFN2-immunoreactivity is observed in the neuronal cytoplasm
of both the control (Case 15) and MSA (Case 1), whereas as the immunoreaction is barely detected both in normal and MSA-oligodendroglia. b:
DRP1 were expressed in the neuronal cytoplasm of both the control and MSA. DRP1 immunoreactivity is seen in some oligodendroglial cell
bodies (arrowheads) in an MSA patient, but not obviously in control. c: Triple-labeling immunofluorescence for TPPP (TPPP-N-mab#2A8G3),
pα-syn, and either DRP1 (left two columns) or TOM20 (right two columns). Accumulation of DRP1 and TOM20 can be seen in types 2 (a blue
arrow for DRP1; a blue arrowhead for TOM20), 3, 4 and 6 oligodendrocytes. d: Western blotting analysis of TOM20 on subcortical white matter
on precentral gyrus in control (Cases 26, 35–37) and MSA (Cases 1, 12–14) patients. There is no significant change of amount of TOM20 between MSA
and controls. Scale bar = 20 μm (a, b), 10 μm (c).
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processes [7,8], two studies previously reported that
TPPP is localized in the nucleus [10,20], consistent with
the present data. Höftberger and colleagues previously
analyzed the localization of TPPP in the human brain by
immunohistochemistry and immunoelectron microscopy,
and showed that TPPP was localized in oligodendroglial
nuclei as well as its cytoplasm [10]. Acevedo and col-
leagues also found similar nuclear localization of TPPP in
the non-neuronal cell lines NIH-3T3 and HeLa using im-
munocytochemistry [20]. As the present investigation and
Höftberger’s study both utilized formic acid to retrieve
hidden antigen, formic acid pretreatment may be required
to detect nuclear TPPP in human formalin-fixed tissue
samples. More importantly, the present observation of the
nuclear localization of TPPP was confirmed with anti-
bodies against both N- and C-termini of TPPP, suggesting
that the full-length protein exists in the oligodendroglial
nucleus. The molecular size of TPPP (25 kDa) suggests
that this protein can passively diffuse into the nucleus from
the cytoplasm through the nuclear pore [31,32]. However,
our finding of three predicted bipartite nuclear localization
signals in TPPP indicates that this protein has the potential
to translocate into the nucleus through the importin α/βpathway, which is highly conserved in eukaryotes [26]. In-
creased nuclear TPPP expression in demyelinating MS pla-
ques also suggests an active role of TPPP in the nucleus.
Then, what is the role of TPPP in the nucleus? Interest-
ingly, TPPP has the classical zinc finger domain His2Cys2
at the amino acid position 61–83 [9]. Although binding of
a zinc ion (Zn2+) to this site has been shown to stabilize
the structure of TPPP and to promote tubulin assembly in
the presence of tubulin in the cytoplasm [9], its possession
of a classical zinc finger motif also implicates its role as a
transcription factor via binding to DNA in the nucleus. It
is interesting to note that OLIG1, another oligodendroglia-
specific protein known as a helix-loop-helix transcription
factor in the nucleus, can translocate into the cytoplasm,
and when phosphorylated, facilitates membrane expansion
leading to the maturation of oligodendroglia [33]. It is thus
possible that TPPP, another phosphorylated protein, has a
dual role depending on its location (i.e., the nucleus or
cytoplasm) within oligodendroglia.
To the best of our knowledge, the present study is the
first to show that TPPP is reduced in the oligodendroglial
nucleus of patients affected with MSA. The reduction of
TPPP from the nucleus is not a secondary phenomenon
related to global cellular dysfunction, since other authentic
Figure 8 Immunohistochemistry for TPPP, synuclein and mitochondrial proteins in a familial MSA patient with homozygous COQ2
defective mutations. Immunohistochemistry in the pons of Case 11 showed numerous pα-syn-positive GCIs (a), the redistribution of TPPP (b),
and DRP1 immuno-positive GCIs (arrowheads) (c). Abnormal accumulation of DRP1 (d) and TOM20 (h), colocalizing with pα-syn (e & i), can be
observed in the GCI (g & k). Scale bar = 50 μm (a-c), 10 μm (d-k).
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retained in the nucleus. We also confirmed the results of
previous studies describing that the immunoreactivity of
TPPP was markedly decreased in the peripheral processes
of MSA-oligodendroglia, whereas TPPP was increased
in the swollen perinuclear cytoplasm of some MSA-
oligodendroglia [8,11,12,27,34,35]. These observations
indicate that TPPP not only relocates from the terminal
processes that normally form the myelin sheath, but
also translocates from the nucleus and focally accumu-
lates in the swollen perinuclear cytoplasm. Song and
colleagues also analyzed the pontine base, and reported
that the accumulation of TPPP in the oligodendroglial
perinuclear cytoplasm precedes the generation of obvi-
ous pα-syn-positive GCIs, the pathologic hallmark of
MSA [8]. Our findings are consistent with this study, as
TPPP was found reduced in the oligodendroglia lacking
GCIs (MSA type 1/types 1 + 2 = 48.63 ± 10.37% vs type
1/types 1 + 2 in controls = 62.4 ± 13.5%; p = 0.0185). In
addition, the prevalence of nuclear TPPP was further
reduced among the MSA-oligodendroglia with pα-syn
immunoreactivity (i.e., GCI-positive oligodendroglia)
(types 3 + 5/types vs 3 + 4 + 5 + 6 in MSA = 19.6 ±
10.9%, p < 0.001). Taking the present results together
with those of Song and colleagues, TPPP appears to re-
locate from both the terminal processes and the nucleusto the perinuclear cytoplasm in oligodendroglia prior to
the formation of GCIs. Yet, it is not clear how the relocali-
zation of TPPP associates with the aggregation of pα-syn
in oligodendroglia. A previous study showed that α-syn is
detected in rat primary culture oligodendroglial cells [36],
suggesting that it could be endogenously upregulated
under certain conditions. Alternatively, α-syn may enter
oligodendroglia through dynamin-mediated endocytosis,
as shown in oligodendroglial cell lines [37,38]. Once α-syn
is expressed in oligodendroglia by means of yet unidenti-
fied mechanisms, it is conceivable that TPPP and α-syn
bind to each other to form aggregates [34,37,38] and to
promote the phosphorylation of α-syn at Serine 129, lead-
ing to microtubule retraction followed by oligodendroglial
cell death [39]. If this is the case, TPPP relocalization
could be an important upstream target for developing
treatments against MSA. However, it should also be noted
that the appearance of GCI may not always indicate a late
stage event in oligodendroglia. To clarify oligodendroglial
pathology, we need to investigate by different methods,
such as cultured cells.
The present study also provides evidence that TPPP is
a mitochondrial protein. Electron microscopic analysis
combined with immunohistochemistry suggested that
TPPP localizes to mitochondria, most frequently to the
outer membrane. Subcellular fractionation experiments
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dria. Although the precise function of TPPP in mitochon-
dria is completely unknown to date, it may be possible
that TPPP plays a role as a mitochondrial motor protein,
considering its binding capacity to tubulin [40]. Similar to
other mitochondrial membrane proteins such as MFN1,
MFN2 or DRP1 [29,41], TPPP demonstrates GTPase ac-
tivity in the presence of zinc [9] and magnesium [21] ions,
suggesting its multiple roles in physiological dynamics (for
example, signal transduction).
We further demonstrated that TPPP is accumulated in
MSA-oligodendroglial cell soma, where the mitochondrial
proteins TOM20, cytochrome C, and DRP1 also showed
stronger immunoreactivity compared to controls. The
present observations using triple immunolabeling for
TPPP, pα-syn, and either TOM20 or DRP1, indicate two
potentially important aspects of MSA-oligodendroglia.
One is that both DRP1 and TOM20 are accumulated in
the pα-syn-positive GCI of MSA-oligodendroglia. Mito-
chondria dynamically control their quality through fusion
and fission, creating their network in the cytoplasm [29].
When the important mitochondrial fission mediator DRP1
is over-activated, it can lead to small and discrete mito-
chondria (mitochondrial fragmentation), and the gener-
ation of reactive oxygen species, and the mitochondria can
be subjected to mitophagy in order to destroy malfunction-
ing mitochondria [29,41]. In a number of neurodegenera-
tive conditions, mitochondrial fission is increased whereas
fusion is impaired, resulting in mitochondrial fragmenta-
tion [41]. Based on the present data, MSA oligodendroglia
may be deviated toward in the hyper-fission state. In
line with this view, parkin, a ubiquitin E3 ligase relevant
to mitophagy, has been shown to be positive in some
GCI-positive oligodendroglia [27]. In addition, small
ubiquitin-like modifier type 1 (SUMO-1), which regu-
lates DRP1 activity, is also positive in some GCIs [42].
Therefore, it is possible that our finding of substantial
DRP1 immunoreactivity in GCI-containing oligodendroglia
reflects abnormal mitochondrial fission leading to mito-
chondrial fragmentation and mitophagy.
The other important implication from this triple-labeling
experiment is that both DRP1 and TOM20 start to ap-
pear before the obvious deposition of pα-syn in MSA-
oligodendroglia. This indicates that abnormal mitochondrial
accumulation, as well as fission, possibly precedes GCI for-
mation. The Multiple System Atrophy Research Consortium
reported that functionally impairing nucleotide variants in
COQ2, which encodes the protein coenzyme Q2 that is es-
sential for the biosynthesis of coenzyme Q10, were associated
with an increased risk of MSA in multiplex families and in
about 10% of sporadic MSA cases [23]. Patients with defect-
ive COQ2 mutations were shown to have GCI-positive
oligodendroglia [23], providing direct evidence for a role of
mitochondrial dysfunction in MSA pathogenesis. In thepresent study, we were able to investigate a patient with this
defective COQ2 mutation, and found that the changes in
the levels of TPPP and the mitochondrial proteins TOM20
and DRP1, as well as the reduction of nuclear TPPP, are
similar to what we observed in sporadic MSA individuals.
In conclusion, we found that TPPP normally localizes
abundantly in the cytoplasm, but also in the nucleus of
some oligodendroglia. TPPP is localized in mitochondria
as well as other cellular component such as cytosol. Based
on our findings and previous descriptions [8,12], in MSA,
we hypothesize that TPPP can relocates not only from the
peripheral processes but also from the nucleus, and ac-
cumulates in the perinuclear cytoplasm. Deposition of
pα-syn and the eventual disappearance of TPPP appear
to follow such TPPP relocation, if our classification of
MSA-oligodendroglia truly reflect MSA-oligodendroglial
pathologic cascade. This hypothesis requires further evalu-
ation from different aspects. For example, technical limita-
tions, such as differences in the affinity of the various
antibodies to their immunogen (i.e., anti-TPPP-antibody
vs anti-α-syn-antibody) should be carefully re-considered.
In vitro experiments such as using oligodendroglial cell
line is required to make the hypothesis evident. Neverthe-
less, the present study suggests the need to discover the
role(s) of TPPP in the nucleus and mitochondria, and how
they are disturbed in MSA. Concerning the TPPP and the
mitochondrial proteins accumulations in the cytoplasm
of MSA-oligodendroglia, the present observation on the
COQ2-mutant MSA case implies that the primary mito-
chondrial dysfunction can lead to the TPPP relocation sec-
ondarily. It is also not known how TPPP relates with these
mitochondrial proteins in a molecular level. Addressing
these questions will provide new information on potential
roles of TPPP in both normal oligodendroglial biology and
MSA pathogenesis.
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